DiaMedica Inc.  

(Public, CVE:DMA)   Watch this stock  
Find more results for DMA
0.0000 (0.00%)
Jan 30 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.06 - 0.09
52 week 0.04 - 1.10
Open 0.06
Vol / Avg. 197,000.00/127,279.00
Mkt cap 4.34M
P/E     -
Div/yield     -
EPS -0.10
Shares 62.03M
Beta -0.21
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -301.84% -228.01%
Return on average equity - -423.77%
CDP Score - -


1 Carlson Pkwy N Ste 124
MINNEAPOLIS, MN 55447-4453
United States - Map
+1-763-2700603 (Phone)
+1-763-7104456 (Fax)

Website links


DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�s DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation.

Officers and directors

Richard D. Pilnik Independent Chairman of the Board
Age: 56
Rick Pauls President, Chief Executive Officer, Director
John Savage Chief Financial Officer
David Gurvey Vice President - Finance
Mark Williams Ph.D. Vice President - Research
Edward Rady Senior Consultant - Licensing and Partnering
James T. Parsons Corporate Secretary
Michael Giuffre MD Independent Director
Dawson J. Reimer Independent Director
Age: 43
Thomas G. Wellner Independent Director